Content by Tecan

The integrated solution enables parallel high-resolution analysis of hundreds to thousands of individual cells, addressing growing demand for scalable, multiomics approaches in single-cell research.

Tecan Group (SIX Swiss Exchange: TECN) today announced an agreement to acquire certain assets relating to key ELISA immunoassay products from Cisbio Bioassays SAS, a subsidiary of the global life sciences and diagnostics company, Revvity Inc.

Multiomics platform streamlines workflows and provides real-time insights, optimizing resource usage and ensuring smooth, data-driven operations

Discover how automation increases the efficiency and reliability of blood-based liquid biopsy assays.

Advancements in measuring DNA in bodily fluids create new opportunities for understanding disease.

Explore how biomolecular processes drive health and disease.

Automated liquid handling workstations offer flexibility for a wide range of application and process needs.

Discover how machine learning helps scientists accelerate their research.  

Explore the latest science shaping the healthcare sector.

Explore the future of biopharma research and development.

Versatile technology helps scientists streamline microbiology research.

Discover how scientists match fluorophores and detectors for accurate measurements.

Understand the ins and outs of detecting luciferase activity.

Researchers produce reliable data when they choose the correct tools for their needs.

Accelerating innovation one wavelength at a time